Drugs moving into the clinic: 12

By Mike Nagle

- Last updated on GMT

Related tags Cancer

The twelfth in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
SponsorNameIndication Mechanism
ExelixisXL999 Oncology - non-small cell lung cancer Inhibits receptor tyrosine kinases (RTKs): FGFR, VEGFR and PDGFR. Plus inhibits FLT3 - acts against tumour vasculature and proliferation. N.B. reinitiation following Phase II adverse cardiovascular events led to FDA trial design review
ExelixisXL765Oncology - undisclosed but preclinical studies in breast, lung, ovarian, and prostate cancers, and gliomasPhospho- inositide-3 kinase (PI3K) inhibitor. Also inhibits mammalian target of rapamycin (mTOR)
SuperGenMP470Oncology - advanced stage solid tumours Multi-targeted tyrosine kinase inhibitor: MET, RET and the mutant forms of KIT, PDGFR and FLT3 as well as suppresses the Rad51 protein
RegenerXT-beta-4Wound healing - Cardio-vascular (post heart attack). N.B. also in PII for chronic dermal and ophthalmic wound healing.43 amino-acid peptide synthetic analog of T-beta-4 - the major actin-regulating molecule in most mammalian cells and plays an important role in the regeneration, remodeling, and healing of injured or damaged tissues. N.B. IND application submission
Pharmexa- Epimmune & Bavarian NordicCombined EP1233 & MVA-BN32 Polytope Anti-infectives and Vaccines - HIV/AIDS Epitope-based DNA vaccine against HIV which activates both helper cells (HTL) and killer cells (CTL). Combined with an jointly owned epitope-matched MVA (Modified Vaccinia Ankara) viral vector vaccine.
Enzon Pharma- ceuticalsPEG-SN38Oncology - solid tumors or lymphomaTopo- isomerase I inhibitor to relieve strain in DNA by enabling reversible single strand breaks. Pegylated form of SN38 - the active metabolite of Pfizer's Camptosar (irinotecan). N.B. IND accepted
Targeted Genetics & University College London's Institute of Ophthalmology, Moorfields Eye Hospital RPE65 Blindness (childhood)Adeno-associated virus (AAV) vector to deliver a normal copy of the RPE65 gene to treat gene defect that prevents normal function of the retina

Related topics Preclinical Research

Related news

Show more